FibroGen, Inc (FGEN) News

FibroGen, Inc (FGEN): $14.47

0.35 (+2.48%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FGEN to Watchlist
Sign Up

Industry: Biotech


Ranked

of 403

in industry

Filter FGEN News Items

FGEN News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FGEN News Highlights

  • FGEN's 30 day story count now stands at 6.
  • Over the past 20 days, the trend for FGEN's stories per day has been choppy and unclear. It has oscillated between 1 and 3.
  • ACRS and BEAT are the most mentioned tickers in articles about FGEN.

Latest FGEN News From Around the Web

Below are the latest news stories about Fibrogen Inc that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

Aclaris Therapeutics (ACRS) Reports Q4 Loss, Misses Revenue Estimates

Aclaris (ACRS) delivered earnings and revenue surprises of -2.78% and 16.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | February 24, 2022

Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for

FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 21, 2022

FibroGen to Report Fourth Quarter and Full Year 2021 Financial Results

SAN FRANCISCO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its fourth quarter and full year 2021 financial results on Monday, February 28 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance. Conference Call and Audio Webcast Interested parties may access a live audio webcast of the conference call via the F

Yahoo | February 14, 2022

FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST.

GlobeNewswire | February 4, 2022

FibroGen to Present at SVB Leerink 11th Annual Global Healthcare Conference

SAN FRANCISCO, Feb. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on Friday, February 18, 2022 at 3:40pm EST. The audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will be available for approximately 30 days. About FibroGen Fibro

Yahoo | February 4, 2022

Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ...

Boston, MA, based Investment company Woodstock Corp (Current Portfolio) buys Amgen Inc, Applied Materials Inc, FedEx Corp, Southwestern Energy Co, Sun Life Financial Inc, sells Reata Pharmaceuticals Inc, Aldeyra Therapeutics Inc, Epizyme Inc, International Business Machines Corp, Omnicom Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Woodstock Corp.

Yahoo | January 7, 2022

FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The on-demand webcast of the session will be available on January 10 at 7:00am EST. The audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investor webpage at www.fibrogen.com. A replay will

Yahoo | January 4, 2022

Does FibroGen (NASDAQ:FGEN) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | January 1, 2022

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones and royalties SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherape

Yahoo | December 20, 2021

A Quick Glance At FibroGen Inc. (NASDAQ: FGEN) Stock: It Is up 33.11% From Its 52-Week Low; YTD, It Is Down -60.18 Percent

During the last session, FibroGen Inc. (NASDAQ:FGEN)s traded shares were 7.55 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stocks price was $14.77, reflecting an intraday gain of 5.50% or $0.77. The 52-week high for the FGEN share is $57.21, that puts it down -287.34 A Quick Glance At FibroGen Inc. (NASDAQ: FGEN) Stock: It Is up 33.11% From Its 52-Week Low; YTD, It Is Down -60.18 Percent Read More »

Marketing Sentinel | December 18, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5313 seconds.